
San Francisco, 02 June 2025: The Report Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery), By End-use, By Region, And Segment Forecasts, 2024 - 2030
The global amyloidosis treatment market size is expected to reach USD 8.91 billion by 2030, registering to grow at a CAGR of 7.4% from 2024 to 2030 according to a new report by Grand View Research, Inc. Several factors such as increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are driving the market.
Amyloidosis is a group of rare diseases where misfolded aggregates of proteins (amyloids) buildup in tissues and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority of cases, the disease is diagnosed in people over the age of 60, there are a few cases of people being diagnosed in their late 20s and about two-thirds of the patients are male.
Stem cell transplants and targeted therapies are gaining traction in developed countries. However, amyloidosis cohorts in endemic regions do not have access to sufficient healthcare infrastructure to ensure prompt diagnosis and treatment in underdeveloped countries. Chemotherapy and supportive care are anticipated to lose market share over the forecast period due to adverse side effects and lower efficacy.
The market growth can be attributed to the rising incidence of amyloidosis among the geriatric population. Amyloidosis is a rare disease characterized by the abnormal buildup of amyloid proteins in organs and tissues, leading to organ dysfunction and severe health complications. These disorders occur in various anatomical regions such as the heart, kidneys, soft tissue, liver, and gastrointestinal tract.
Request sample report of Amyloidosis Treatment Market@ https://www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market/request/rs1
The market growth was propelled by the increased number of patients with genetic mutations in blood cell DNA and underlying plasma cell disorders such as monoclonal gammopathy and myeloma. This led to the increased adoption of amyloid stabilizers to stabilize the amyloid protein and prevent its accumulation in tissues and organs, further aiding market growth. Moreover, increased demand for treatments such as chemotherapy, transplantation, and other treatments has driven the market.
Early and accurate diagnosis of amyloidosis is essential for effective treatment. Recent advancements in diagnostic technologies, such as imaging techniques and biomarker identification, have significantly improved the detection and diagnosis of amyloidosis. These advancements enable healthcare providers to identify the disease earlier, leading to better patient outcomes and increased demand for diagnostic services. For instance, the introduction of monoclonal antibodies and small molecule inhibitors has revolutionized the treatment landscape for amyloidosis, providing patients with more effective and personalized treatment options.
Moreover, heavy investments made by government initiatives for research and development activities have fueled the market growth. This surge in R&D investment is driven by the growing recognition of the unmet medical needs in the amyloidosis market and the potential for significant market opportunities. Companies have increasingly focused on developing drugs and treatments that effectively prevent the buildup with reduced side effects. In addition, growth in healthcare infrastructure and increased disposable income have encouraged patients to seek technologically advanced drugs and treatments to cure amyloidosis.